Canaccord analyst Jason Mills noted Boston Scientific reported solid Q3 results and said there was nothing in the report to imply a loss of momentum. The analyst believes the company will enter 2019 with its best fundamentals in its history and is very well positioned to deliver organic revenue growth above its peers. Mills reiterated his Buy rating and raised his price target to $42 from $40 on Boston Scientific shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.